Document 0091
 DOCN  M9550091
 TI    [New drugs against tuberculosis and nontuberculous mycobacterial
       infections: a review]
 DT    9505
 AU    Amitani R; Kuze F; Department of Infection and Inflammation, Kyoto
       University,; Japan.
 SO    Kekkaku. 1994 Nov;69(11):711-7. Unique Identifier : AIDSLINE
       MED/95139537
 AB    The number of cases with tuberculosis is again increasing in many
       countries, and recently several nosocomial outbreaks of
       multidrug-resistant tuberculosis have occurred in the United States. The
       number of patients with disseminated Mycobacterium avium complex (MAC)
       infections in AIDS population, and patients with MAC pulmonary disease
       unassociated with HIV seem to be also increasing. It takes at least 6 to
       9 months for an initial treatment of active tuberculosis due to
       drug-sensitive strains with the standard regimen which includes
       isoniazid (INH) and rifampicin (RFP). Treatment for the diseases caused
       by drug-resistant M. tuberculosis and MAC is much more time-consuming
       and more toxic than for the diseases caused by drug-sensitive strains,
       and often unsuccessful. For the reasons described above, the
       developments of new agents with potent antimycobacterial activities are
       highly desired. The new agents should also be useful for treating
       patients who have acquired resistance to many of the currently available
       drugs. In this review the new antimycobacterial drugs are summarized.
       Some of them have already been used clinically, but many are still in
       experimental evaluations. 1) Rifamycin derivatives: rifabutin (RBT),
       KRM-1648 (KRM), rifapentin (RPT), FCE-22250, FCE-22807, CGP-7040,
       SPA-S-565 and other rifamycin derivatives. New rifamycin derivatives
       including RBT, KRM have increased in vitro antimycobacterial activities.
       RBT and KRM are much more active in vitro and in vivo than RFP against
       both M. tuberculosis and MAC. KRM seems to be more potent than RBT
       against MAC in experimental studies.(ABSTRACT TRUNCATED AT 250 WORDS)
 DE    Animal  Antitubercular Agents/*THERAPEUTIC USE  English Abstract  Human
       Male  Mice  Mycobacterium avium-intracellulare Infection/DRUG THERAPY
       Mycobacterium Infections, Atypical/*DRUG THERAPY  Tuberculosis/*DRUG
       THERAPY  JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).